# Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

> **NCT04912115** · PHASE2 · SUSPENDED · sponsor: **PharmaTher Inc.** · enrollment: 30 (actual)

## Conditions studied

- Dyskinesias
- Movement Disorders
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT04912115
- **Lead sponsor:** PharmaTher Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-10-05
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Seeking Pivotal study initiation
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04912115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04912115, "Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04912115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*